Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease
Citations Over TimeTop 10% of 2016 papers
Abstract
Coronary heart disease (CHD) is top risk factor for health in modern society, causing high mortality rate each year. However, there is no reliable way for early diagnosis and prevention of CHD so far. So study the mechanism of CHD and development of novel biomarkers is urgently needed. In this study, metabolomics and metagenomics technology are applied to discover new biomarkers from plasma and urine of 59 CHD patients and 43 healthy controls and trace their origin. We identify GlcNAc-6-P which has good diagnostic capability and can be used as potential biomarkers for CHD, together with mannitol and 15 plasma cholines. These identified metabolites show significant correlations with clinical biochemical indexes. Meanwhile, GlcNAc-6-P and mannitol are potential metabolites originated from intestinal microbiota. Association analysis on species and function levels between intestinal microbes and metabolites suggest a close correlation between Clostridium sp. HGF2 and GlcNAc-6-P, Clostridium sp. HGF2, Streptococcus sp. M143, Streptococcus sp. M334 and mannitol. These suggest the metabolic abnormality is significant and gut microbiota dysbiosis happens in CHD patients.
Related Papers
- → A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice(2013)355 cited
- → Microbial metabolomics: Toward a platform with full metabolome coverage(2007)206 cited
- → The use of metabolomics for the discovery of new biomarkers of effect(2007)204 cited
- → Mouse Age Matters: How Age Affects the Murine Plasma Metabolome(2020)13 cited
- → Metabolomics: Metabolome measurement in human plasma(2006)